After decades of determined research, RNAi drugs have their day in the sun
A panel at Biotech Showcase last week provided an outlook for a new class of drugs that only entered the market two years ago, but was decades in the making.
Novartis wraps up $9.7B Medicines Company buyout
The deal was originally announced in November. The Medicines Co.'s lead product candidate is inclisiran, an RNAi drug for reducing cholesterol, for which it submitted an FDA approval application in December.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Foresight is 2020: A look at what’s ahead for biopharma
Executives from biopharma companies and an academic expert weigh in on what's in store for areas like cell and gene therapy, precision medicine and drug pricing.
Dicerna, Roche ink $200M development, commercialization deal for chronic hep B drugs
The partnership will primarily focus on the drug DCR-HBVS, an RNA-interference drug that Dicerna is developing for HBV. The deal includes potential milestones of up to $1.47 billion.
Sirnaomics closes second portion of $47M Series C round for RNA-interference drugs
The firm announced that it closed a $22 million Series C2 round, following a $25 million Series C1 round that it had closed last June, led by Asian investors.
Alnylam, Regeneron form $1B partnership to develop eye, central nervous system drugs
The deal will focus on discovery, development and commercialization of CNS and eye drugs and also includes development of two C5-targeting drugs in liver disease. The companies have an existing partnership centered on NASH drugs.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
FDA approves Alnylam’s siRNA drug Onpattro for rare disorder
The drug is the first approved treatment for the condition, as well as the first siRNA drug to win the agency's approval.
Sirnaomics raises $25 million in Series C1 round for RNAi drug
Firm raises funding for RNAi therapy's clinical development from group of Chinese funds.
Alnylam stages a comeback with positive late-stage study results for RNAi treatment Patisiran
Promising Phase 3 study results for its RNAi treatment, called Patisiran, for a rare, genetic nerve disorder have increased the chances that Alnylam could be the first to commercialize a RNAi drug.
Purdue and Exicure sign deal worth up to $790M
Purdue Pharma has announced a strategic partnership with Exicure, which could be worth up to $790 million and royalties if the latter's drug candidates succeed. The first disease target, psoriasis, is well outside of Purdue's painkiller market -- probably not by accident.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Can Alnylam rise from the ASHes?
After its shares plunged nearly 50 percent in October, Alnylam, the double-stranded RNAi company, is trying to resurrect itself with new data at the annual meeting of the American Society of Hematology (ASH).
5AM Ventures launching stealth (RNA?) startup Homology Medicines with $23M
Its core science comes from Harvard Stem Cell Institute researcher Richard Gregory, who focuses on the function of miRNA in disease manifestation. We're guessing Homology Medicines is in this field as well.
That RNAi startup whose founder was shot by a disgrunted biotech exec just raised $7.5M
Solstice Biologics, an interesting RNAi therapeutics company that has attracted attention for the wrong reasons, has raised $7.5 million, according to a regulatory filing, building on the $18 million raised last year from venBio and Aeris Capital. The San Francisco company is figuring out how to get RNAi-based drugs to cross multiple cell types to treat different […]